Rapamycin: New Rapamycin CEO Hired to Handle Funding, FDA Inflection Points

San Antonio - Rapamycin Holdings has a new CEO, is raising a $3.5 million Series B round of funding, and plans to submit an investigational new drug filing to the FDA this year. If all goes well, the small biotech may start its first in-human clinical trials as early as later this year. "The company is [...]